Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial | BMJ

Eric K. Noji, M.D.‘s insight:

Doubling the dose of oseltamivir (Tamiflu, Genentech USA, Inc) for patients hospitalized with severe influenza provides no virological or clinical advantages over standard dosing, according to an article published online May 30 in the British Medical Journal. This finding could help preserve drug stocks in a future pandemic

See on www.bmj.com

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s